Single-sided Deafness and Cochlear Implants

Sponsor
University of Zurich (Other)
Overall Status
Completed
CT.gov ID
NCT01749592
Collaborator
(none)
20
1
1
62.3
0.3

Study Details

Study Description

Brief Summary

  • As the left and right hemisphere are specialized for different auditory tasks, the proposed study aims at demonstrating different consequences of right or left-sided deafness for the affected individual.

  • Furthermore, the question should be answered if auditory deficits and plastic changes can be partially reversed by cochlear implantation of the deaf ear.

  • Multicenter, prospective, open, non-randomized clinical trial with 5 patients with right-sided and 5 patients with left-sided sensineural deafness.

  • Pre-operative: Audiometry, Sound Localization Audiometry, PET, EEG/MEG

  • Comparison of pre-operative investigations with 10 healthy subjects (age and gender matched control group)

  • Cochlea implantation

  • Follow-up Visits at 3, 6, 9 and 12 month post-operative: Audiometry, Sound Localization Audiometry, PET, EEG, Questionnaires

  • Trial with medical device

Condition or Disease Intervention/Treatment Phase
  • Device: cochlear implant
N/A

Detailed Description

Postlingual single-sided deafness (SSD) is a type of hearing impairment with normal hearing in one ear and severely impaired hearing in the other ear. The condition induces multiple changes of neural plasticity in central auditory pathways. One manifestation reflects an increased common activation of the contralateral and ipsilateral pathways after stimulation of the normal hearing ear which is correlated with an increased activity between the contralateral and ipsilateral hemispheres. As the left and right hemisphere are specialized for different auditory tasks, the proposed study aims at demonstrating different consequences of right or left-sided deafness for the affected individual. Furthermore, the question should be answered if auditory deficits and plastic changes can be partially reversed by cochlear implantation of the deaf ear. It is assumed that some changes induced by SSD can be detected only by reversal through a cochlear implant.

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Hemispheric Dominance in Single-sided Postlingual Deafness and Changes / Plasticity Induced by Cochlear Implants
Study Start Date :
Dec 1, 2012
Actual Primary Completion Date :
Jan 1, 2018
Actual Study Completion Date :
Feb 8, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cochlear Implant

Surgical Implantation of a Cochlear Implant

Device: cochlear implant
Surgical implantation of a cochlear implant device

Outcome Measures

Primary Outcome Measures

  1. Audiometry [up to12 months after invention]

    Pure tone audiometry Speech audiometry Sound localization in both quiet and noise

Secondary Outcome Measures

  1. PET scan [9 months after intervention]

    [15O] H2O Positron emission tomography (PET) is performed. The comparison of baseline PET scans and stimulated PET scans will demonstrate task related changes in brain activity

Other Outcome Measures

  1. EEG [3, 6 and 12 months after intervention]

    Resting state EEG and EEG with acoustic paradigm.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion criteria: • Patients with acquired single sided sensorineural deafness due to cochlear damage.

  • Age: 18-70 years old.

  • Onset of SSD within 6 months to 10 years before Study inclusion.

  • Normal hearing on the contralateral ear (Hearing thresholds 0.125-2 kHz 25 dB HL or better, 4-8 kHz 35 dB HL or better, 100% speech discrimination at 80 dB SPL).

  • Regular middle ear function on the hearing ear.

  • Regular structure of the cochlea and the cochlear nerve (as demonstrated by MRI, MRI scans are included in the basic assessment of SSD and are no study-specific investigations).

  • Fluency in the German language.

  • Subject is willing to comply with all study requirements.

  • Impairment in daily life as a consequence of SSD (communication problems, annoyance by tinnitus perception).

  • Subject is not participating in another ongoing research study related to the SSD.

  • Subject does not have unrealistic expectations, regarding the outcome of the intervention.

  • Subject has had a trial with conventional acoustic measures in SSD (CROSS, BAHA).

Exclusion criteria: • Uncertainty of correct diagnosis of SSD.

  • Retrocochlear cause of SSD (Deafness due to lesions of the acoustic nerve or central auditory pathways).

  • Active middle ear infections.

  • Ossification of the cochlear that prevents electrode insertion.

  • Tympanic membrane perforation.

  • Psychiatric comorbidities such as depression or cognitive deficits.

  • Severe coexisting illness with a medium survival of less than 5 years.

  • Exposure to radiation with a cumulative effective dose of 5 mSV within the last 5 years (including the ongoing year).

  • Increased risk profile for general anesthesia due to cardiovascular comorbidity.

  • Metallic implants constituting an exclusion criterium for MEG procedures of the brain.

  • Pregnancy (a pregnancy test will be performed in women in the reproductive age group before study enrolment and before postoperative PET scan) and lactation.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital Zurich, Division of Otorhinolaryngology ORL Zurich ZH Switzerland 8091

Sponsors and Collaborators

  • University of Zurich

Investigators

  • Principal Investigator: Tobias Kleinjung, MD, University Hospital Zurich, Division of Otorhinolaryngology ORL

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Zurich
ClinicalTrials.gov Identifier:
NCT01749592
Other Study ID Numbers:
  • 2012-0034
First Posted:
Dec 13, 2012
Last Update Posted:
Sep 9, 2020
Last Verified:
Sep 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Zurich
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 9, 2020